Influence of different susceptibility testing methods and media on determination of the relevant fluconazole minimum inhibitory concentrations for heavy trailing Candida isolates with low-high phenotype

Mycoses

Volumn 53, Issue 6, 2010, Pages 475-480

  Alp, Sehnaz ^a   Sancak, Banu ^a   Hascelik, Gulsen ^a   Arikan, Sevtap ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Broth Microdilution; Candida; Etest; Fluconazole; Trailing Growth

Indexed keywords

FLUCONAZOLE; GLUCOSE; METHYLENE BLUE;

AGAR DILUTION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA TROPICALIS; CONTROLLED STUDY; EPSILOMETER TEST; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDA TROPICALIS; CULTURE MEDIA; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE;

CANDIDA; CANDIDA ALBICANS; CANDIDA TROPICALIS;

EID: 77958101390     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01739.x     Document Type: Article

References (21)

1. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. NCCLS document M27-A2. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
2. Pfaller MA. Antifungal susceptibility testing methods. Curr Drug Targets 2005; 6: 929-43.
3. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-47.
4. Rex JH, Pfaller MA, Galgiani JN et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin Infect Dis 1997; 24: 235-47.
5. Arthington-Skaggs BA, Lee-Yang W, Ciblak MA et al. Comparison of visual and spectrophotometric methods of broth microdilution MIC endpoint determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob Agents Chemother 2002; 46: 2477-81.
6. Marr KA, Rustad TR, Rex JH, White TC. The trailing endpoint phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 1999; 43: 1383-6.
7. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol 2007; 45: 569-87.
8. Rex JH, Nelson PW, Paetznick VL, Lozano-Chiu M, Espinel-Ingroff A, Anaissie EJ. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob Agents Chemother 1998; 42: 129-34.
9. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invasive candidiasis. Antimicrob Agents Chemother 2000; 44: 2081-5.
10. Revankar SG, Kirkpatrick WR, McAtee RK et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J Clin Microbiol 1998; 36: 153-6.
11. Barry AL, Pfaller MA, Rennie RP, Fuchs PC, Brown SD. Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods. Antimicrob Agents Chemother 2002; 46: 1781-4.
12. Pfaller MA, Messer SA, Karlsson A, Bolmström A. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J Clin Microbiol 1998; 36: 2586-9.
13. Pfaller MA, Messer SA, Houston A, Mills K, Bolmstrom A, Jones RN. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J Clin Microbiol 2000; 38: 3715-7.
14. Simor AE, Goswell G, Louie L, Lee M, Louie M. Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the Etest. Eur J Clin Microbiol Infect Dis 1997; 16: 693-7.
15. Larone DH. Medically Important Fungi: A Guide to Identification, 3rd edn. Washington, DC: ASM Press, 1995.
16. Barry AL, Pfaller MA, Brown SD et al. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J Clin Microbiol 2000; 38: 3457-9.
17. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts. Approved guideline. CLSI/NCCLS document M44-A. Wayne, PA: Clinical and Laboratory Standards Institute, 2004.
18. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol 2007; 45: 3522-8.
19. Matar MJ, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob Agents Chemother 2003; 47: 1647-51.
20. Cantón E, Pemán J, Sastre M, Valentín A, Bosch M, Espinel-Ingroff A. Evaluation and utility of the E-test and Neo-Sensitabs methods in studying fluconazole yeast susceptibility. Rev Esp Quimioter 2006; 19: 267-74 (Article in Spanish).
21. Capoor MR, Rawat D, Nair D, Deb M, Aggarwal P. Evaluation of glucose-methylene-blue-mueller-hinton agar for E-test minimum inhibitory concentration determination in Candida spp. Indian J Med Microbiol 2007; 25: 432-3.